Form 4: Fortress Biotech Boosts ATXI Stake with Dividend Shares

Fortress Biotech, Inc. increased its beneficial ownership in Avenue Therapeutics, Inc. by 111,209 shares of common stock as an annual dividend.

Summary

• Fortress Biotech, Inc. (the "Reporting Person") acquired 111,209 shares of common stock of Avenue Therapeutics, Inc. (ATXI).
• The transaction occurred on January 2, 2026.
• The shares were granted as an annual dividend on Fortress Biotech's Class A Preferred Stock.
• This dividend is equal to 2.5% of Avenue Therapeutics' fully diluted outstanding capitalization as of December 31.
• Following this transaction, Fortress Biotech, Inc. beneficially owns a total of 439,733 shares of Avenue Therapeutics, Inc. common stock.
• The acquisition price per share was $0, as it was a dividend grant.
• Fortress Biotech, Inc. is identified as both a Director and a 10% Owner of Avenue Therapeutics, Inc.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as a significant shareholder received a dividend in shares, increasing their stake. This indicates a return on investment for Fortress Biotech and a routine fulfillment of obligations by Avenue Therapeutics. It's not highly positive as it's a pre-scheduled event rather than a new strategic investment.

Positives

• Fortress Biotech, Inc. received 111,209 shares of Avenue Therapeutics, Inc. common stock as a dividend, increasing its beneficial ownership.
• The dividend reflects a return on Fortress Biotech's investment in Avenue Therapeutics' Class A Preferred Stock.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the nature of the annual dividend entitlement.

Industry Context

This transaction represents a routine insider ownership update, where a significant shareholder and director receives an annual dividend in shares, reflecting a pre-existing financial arrangement. Such transactions are common in the biotechnology and pharmaceutical sectors, where strategic investments and partnerships often include preferred stock with dividend provisions.

Related Party Transactions

• Fortress Biotech, Inc., a 10% owner and director of Avenue Therapeutics, Inc., received 111,209 shares of common stock as an annual dividend on its Class A Preferred Stock. This transaction is between related parties based on Fortress Biotech's significant ownership and board representation.

Stakeholder Impact

• Shareholders of Avenue Therapeutics, Inc. will see an increase in beneficial ownership by a significant institutional investor and director, Fortress Biotech, Inc., which could be viewed as a sign of continued commitment.
• Fortress Biotech, Inc. shareholders benefit from the increased equity stake in Avenue Therapeutics, Inc. through the dividend.

Key Dates

Keywords

Fortress Biotech, Avenue Therapeutics, ATXI, SEC Form 4, Beneficial Ownership, Common Stock, Dividend, Insider Transaction